ImmunArray
Operating Status: Closed
ImmunArray, a molecular diagnostics firm, pioneers in accurate lupus detection through proprietary testing.
Founded
2006ImmunArray, a molecular diagnostics firm, pioneers in accurate lupus detection through proprietary testing.
Founded in 2006, ImmunArray is a molecular diagnostics company dedicated to improving the accuracy of autoimmune disease diagnosis, with a core mission to enhance patient care through innovative testing solutions. The company's flagship product is a proprietary test designed to rule out lupus in blood samples, addressing the challenge of misdiagnosis and inappropriate treatment that often accompanies this complex disease. ImmunArray's focus is on providing reliable diagnostic tools to healthcare providers, thereby improving patient outcomes in the autoimmune disease market.
Notable figures associated with ImmunArray include key investors and advisors from the medical and biotech industries, though specific names are not publicly highlighted. The company has achieved significant milestones, including the successful introduction of its lupus diagnostic test, which has been recognized for its potential to transform lupus diagnosis. ImmunArray's impact lies in its contribution to reducing diagnostic errors and enhancing the precision of autoimmune disease management, positioning it as a critical player in the molecular diagnostics landscape.
Companies similar to ImmunArray include ImmunoProfile, Arrayit, Thera-Test Laboratories and Progentec Diagnostics.
ImmunArray was founded in 2006.
ImmunArray's headquarters is located in Richmond, VA, US.
ImmunArray's most recent funding round was for $10M (USD) in July 2016.
As of Jul 12, 2016, ImmunArray has disclosed funding of $10M (USD). Undisclosed round amounts are excluded.
Progentec Diagnostics
progentec.com
